

DOCON TECHNOLOGIES PRIVATE LIMITED

April 20, 2026

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051	To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001
To, Thyrocare Technologies Limited D37/3, TTC MIDC, Turbhe, Navi Mumbai – 400073	

Sub: Update to earlier disclosures under Regulation 31 of SEBI (SAST) Regulations, 2011 in respect of encumbrance on shares of Thyrocare Technologies Limited – Partial redemption of Series 1 Non-Convertible Debentures through reduction of face value

Dear Sir & Madam,

We refer to our earlier disclosures dated September 24, 2025, November 11, 2025, December 05, 2025 and March 31, 2026, made under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SEBI SAST Regulations”), in respect of the encumbrance created by Docon Technologies Private Limited (“Docon”), Promoter of Thyrocare Technologies Limited (“the Company”), in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee for the Non-Convertible Debentures (“NCDs”) issued by API Holdings Limited, the holding company of Docon.

Please note that API Holdings Limited has partially redeemed its Series 1 Non-Convertible Debentures on April 16, 2026, by way of reduction in the face value per debenture from INR 9,00,000 to INR 8,75,000 per debenture, pursuant to which an aggregate amount of INR 300 million has been paid towards partial redemption. Accordingly, the outstanding principal amount of the Series 1 Non-Convertible Debentures stands reduced from INR 10,800 million to INR 10,500 million.

Pursuant to the aforesaid, there is **no change in the number of encumbered shares of Thyrocare Technologies Limited held by Docon**. However, certain details last disclosed on March 31, 2026 (including outstanding principal amount and particulars of the debenture holders) have been updated to reflect the current position.

The updated details are enclosed in **Annexure 1** in the format prescribed under the Regulation 31 of the SEBI SAST Regulations.

You are requested to take the same on record.

For Docon Technologies Private Limited


Madhuri Sudhir Sarangdhar
Company Secretary



Encl: **Annexure 1**

DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure 1

Format for disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 – Annexure 1

Name of the Target Company (TC)					Thyrocare Technologies Limited (“Thyrocare”)								
Names of the stock exchanges where the shares of the target company are listed					1. BSE Limited 2. National Stock Exchange of India Limited								
Date of reporting					April 20, 2026								
Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked					Promoter: Docon Technologies Private Limited PAC: API Holdings Limited								
Details of the creation of encumbrance													
Name of the promoter(s) or PACs with him*	Promoter holding in the target company (1)		Promoter holding already encumbered (2)		Details of events pertaining to encumbrance (3)							Post event holding of Encumbered shares {creation [(2)+(3)] / release [(2)-(3)] / invocation [(1)-(3)]}	
	Number	% of total share capital	Number	% of total share capital	Type of event (creation /Release /-invocation)	Date of creation /-release/- invocation of encumbrance	Type of encumbrance (pledge/line/-non disposal undertaking / others)	Reasons for encumbrance **	Number	% of share capital	Name of the entity in whose favor shares Encumbered ***	Number	% of total share capital
Docon Technologies	9,69,69,696	60.92	9,69,69,696	60.92	Update to earlier disclosures	API Holdings Limited has	Others# # API Holdings	The encumbrance on shares	9,69,69,696	60.92	The Shares has been pledged with Catalyst Trusteeship Limited as	9,69,69,696	60.92



DOCON TECHNOLOGIES PRIVATE LIMITED

s Private Limited ("Docon")					<p>under Regulation 31 of the SEBI (SAST) Regulations, 2011 in respect of encumbrance on shares of Thyrocare Technologies Limited – partial redemption of Series 1 non-convertible debentures.</p>	<p>partially redeemed its Series 1 Non-Convertible Debentures on April 16, 2026, by way of reduction in the face value per debenture from INR 9,00,000 to INR 8,75,000 per debenture, pursuant to which an aggregate amount of INR 300 million has been paid towards partial redemption.</p>	<p>Limited has partially redeemed its Series 1 Non-Convertible Debentures on April 16, 2026, by way of reduction in the face value per debenture from INR 9,00,000 to INR 8,75,000 per debenture, pursuant to which an aggregate amount of INR 300 million has been paid towards partial redemption.</p>	<p>has been created pursuant to a corporate guarantee extended by Docon Technologies Private Limited ("Docon") to secure the obligations of API Holdings Limited ("API"), the holding company, in respect of facilities availed by API through issuance of unlisted, unrated, secured, redeemable, non-</p>			<p>Debenture Trustee for Debenture issued by API.</p> <p>Details of Debenture Issued by API: 12,000 (Twelve Thousand) unlisted, unrated, secured, redeemable, non-convertible debentures, pursuant to partial redemption the face value stands reduced from INR 9,00,000 to INR 8,75,000 per debenture, aggregating to a nominal value of INR 10,500 million (Indian Rupees Ten Thousand Five Hundred Million only) ("Series 1 Debentures").</p> <p>Details of Debenture Holders/Investors for Series 1 Debenture:</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;">Name</th> <th style="width: 30%;">Amount (in Million)</th> </tr> </thead> <tbody> <tr> <td>360 ONE INCOME OPPORTUNITIES FUND - SERIES 3</td> <td style="text-align: center;">297.5</td> </tr> <tr> <td>360 ONE COMMERCIAL YIELD FUND</td> <td style="text-align: center;">787.5</td> </tr> </tbody> </table>	Name	Amount (in Million)	360 ONE INCOME OPPORTUNITIES FUND - SERIES 3	297.5	360 ONE COMMERCIAL YIELD FUND	787.5
Name	Amount (in Million)																
360 ONE INCOME OPPORTUNITIES FUND - SERIES 3	297.5																
360 ONE COMMERCIAL YIELD FUND	787.5																



DOCON TECHNOLOGIES PRIVATE LIMITED

							been paid towards partial redemption. Accordingly, the outstanding principal amount of the Series 1 Non-Convertible Debentures stands reduced from INR 10,800 million to INR 10,500 million.			BENNETT COLEMAN AND COMPANY LIMITED	437.5		
										URMILA BEHERA	12.25		
										NIRAJ INTEX LLP	131.25		
										WARMOND FIDUCIARY SERVICES LIMITED	12.25		
										WARMOND FIDUCIARY SERVICES LIMITED	22.75		
										WARMOND FIDUCIARY SERVICES LIMITED	22.75		
										WARMOND FIDUCIARY SERVICES LIMITED	5.25		
										MVS VENTURES PRIVATE LIMITED	58.625		
										ALKRAM VENTURE PRIVATE LIMITED	58.625		
										WARMOND FIDUCIARY SERVICES LIMITED	17.5		
										WARMOND FIDUCIARY SERVICES LIMITED	35		
										WARMOND FIDUCIARY SERVICES LIMITED	17.5		
										WARMOND FIDUCIARY SERVICES LIMITED	12.25		



